The Journal of Immunology, Vol 142, Issue 2 394-402, Copyright © 1989 by American Association of Immunologists

ARTICLES

Delineation of several DR-restricted tetanus toxin T cell epitopes

S Demotz, A Lanzavecchia, U Eisel, H Niemann, C Widmann and G Corradin
Institut de Biochimie, Universite de Lausanne, Epalinges, Switzerland.

We have characterized five human T cell clones specific for tetanus toxin. The combination of different techniques allowed us to precisely map two T cell epitopes within fragments 830-843 and 1273-1284 of tetanus toxin, as formally demonstrated by the use of corresponding synthetic peptides. The three other T cell clones were specific for regions 2-602, 604-742, and 865-1315 of tetanus toxin, respectively. The five T cell clones were shown to be restricted to HLA-DR Ag. Furthermore, the allele of HLA-DR utilized by the various epitopes has been determined. The use of HLA-DR-transfected L cells as APC directly demonstrated that two epitopes, one of which represented by fragment 1273-1284, were recognized in association with HLA-DRw52a. For the other three T cell epitopes, the data strongly suggested they were recognized in association with HLA-DR5. Finally, a sixth T cell clone was shown to be specific for tetanus toxoid, the vaccinal preparation of tetanus toxin, and not for other tetanus toxin fragments. This indicated that immunization with tetanus toxoid probably elicits a T cell response directed only in part against native tetanus toxin.

This article has been cited by other articles:

				J. N. Radcliffe, J. S. Roddick, F. K. Stevenson, and S. M. Thirdborough Prolonged Antigen Expression following DNA Vaccination Impairs Effector CD8+ T Cell Function and Memory Development J. Immunol., December 15, 2007; 179(12): 8313 - 8321. [Abstract] [Full Text] [PDF]

				E. A. James, J. Bui, D. Berger, L. Huston, M. Roti, and W. W. Kwok Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition Int. Immunol., November 1, 2007; 19(11): 1291 - 1301. [Abstract] [Full Text] [PDF]

				C. Barbey, E. Pradervand, N. Barbier, and F. Spertini Ex Vivo Monitoring of Antigen-Specific CD4+ T Cells after Recall Immunization with Tetanus Toxoid Clin. Vaccine Immunol., September 1, 2007; 14(9): 1108 - 1116. [Abstract] [Full Text] [PDF]

				J. N. Radcliffe, J. S. Roddick, P. S. Friedmann, F. K. Stevenson, and S. M. Thirdborough Prime-Boost with Alternating DNA Vaccines Designed to Engage Different Antigen Presentation Pathways Generates High Frequencies of Peptide-Specific CD8+ T Cells J. Immunol., November 15, 2006; 177(10): 6626 - 6633. [Abstract] [Full Text] [PDF]

				K. A. Chianese-Bullock, J. Pressley, C. Garbee, S. Hibbitts, C. Murphy, G. Yamshchikov, G. R. Petroni, E. A. Bissonette, P. Y. Neese, W. W. Grosh, et al. MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma J. Immunol., March 1, 2005; 174(5): 3080 - 3086. [Abstract] [Full Text] [PDF]

				S. K. Dissanayake, J. A. Thompson, J. J. Bosch, V. K. Clements, P. W. Chen, B. R. Ksander, and S. Ostrand-Rosenberg Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines: A Novel Cell-based Immunotherapy Cancer Res., March 1, 2004; 64(5): 1867 - 1874. [Abstract] [Full Text] [PDF]

				C. L. Slingluff Jr, G. R. Petroni, G. V. Yamshchikov, D. L. Barnd, S. Eastham, H. Galavotti, J. W. Patterson, D. H. Deacon, S. Hibbitts, D. Teates, et al. Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells J. Clin. Oncol., November 1, 2003; 21(21): 4016 - 4026. [Abstract] [Full Text] [PDF]

				R. Laub, R. Brecht, M. Dorsch, U. Valey, K. Wenk, and F. Emmrich Anti-Human CD4 Induces Peripheral Tolerance in a Human CD4+, Murine CD4-, HLA-DR+ Advanced Transgenic Mouse Model J. Immunol., September 15, 2002; 169(6): 2947 - 2955. [Abstract] [Full Text] [PDF]

				A.-S. Beignon, J.-P. Briand, R. Rappuoli, S. Muller, and C. D. Partidos The LTR72 Mutant of Heat-Labile Enterotoxin of Escherichia coli Enhances the Ability of Peptide Antigens To Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin Infect. Immun., June 1, 2002; 70(6): 3012 - 3019. [Abstract] [Full Text] [PDF]

				C. L. Slingluff Jr., G. Yamshchikov, P. Neese, H. Galavotti, S. Eastham, V. H. Engelhard, D. Kittlesen, D. Deacon, S. Hibbitts, W. W. Grosh, et al. Phase I Trial of a Melanoma Vaccine with gp100280-288 Peptide and Tetanus Helper Peptide in Adjuvant: Immunologic and Clinical Outcomes Clin. Cancer Res., October 1, 2001; 7(10): 3012 - 3024. [Abstract] [Full Text] [PDF]

				W. Wienhold, G. Malcherek, C. Jung, S. Stevanovic, G. Jung, H. Schild, and A. Melms An example of immunodominance: engagement of synonymous TCR by invariant CDR3{beta} Int. Immunol., June 1, 2000; 12(6): 747 - 756. [Abstract] [Full Text] [PDF]

				K. C. El Kasmi, S. Fillon, D. M. Theisen, H. Hartter, N. H. C. Brons, and C. P. Muller Neutralization of measles virus wild-type isolates after immunization with a synthetic peptide vaccine which is not recognized by neutralizing passive antibodies J. Gen. Virol., March 1, 2000; 81(3): 729 - 735. [Abstract] [Full Text]

				J. A. Zaia, J.G. P. Sissons, S. Riddell, D. J. Diamond, M.R. Wills, A.J. Carmichael, M.P. Weekes, M. Gandhi, C. La Rosa, M. Villacres, et al. Status of Cytomegalovirus Prevention and Treatment in 2000 Hematology, January 1, 2000; 2000(1): 339 - 355. [Abstract] [Full Text] [PDF]

				N. Nagvekar, L. Corlett, L. W. Jacobson, H. Matsuo, R. Chalkley, P. C. Driscoll, S. Deshpande, E. G. Spack, and N. Willcox Scanning a DRB3*0101 (DR52a)-Restricted Epitope Cross-Presented by DR3: Overlapping Natural and Artificial Determinants in the Human Acetylcholine Receptor J. Immunol., April 1, 1999; 162(7): 4079 - 4087. [Abstract] [Full Text] [PDF]